(MYND) Mynd.ai - Ratings and Ratios

Mynd.ai, Inc. (NYSE MKT: MYND) is a subsidiary of NetDragon Websoft Holdings Limited, specializing in the development and deployment of artificial intelligence and machine learning technologies within the healthcare sector. The company focuses on creating AI-driven solutions to enhance clinical decision-making, operational efficiency, and patient outcomes. Mynd.ais platform integrates advanced algorithms with real-world healthcare data to deliver actionable insights for providers, payers, and patients. For more information, visit their website: https://www.mynd.ai.

As of the latest data, Mynd.ai, Inc. is listed on the NYSE MKT under the ticker symbol MYND, classified as a common stock. The company is incorporated in the Cayman Islands and operates within the Health Care Technology sub-industry. Mynd.ais market capitalization stands at $49.21 million USD, with a price-to-book ratio of 0.64, indicating a moderate valuation relative to its book value. The company currently operates with a return on equity (RoE) of 9.41%, reflecting its ability to generate profits from shareholder equity.

From a technical standpoint, Mynd.ai, Inc. has shown recent price action trading at $1.15, with a 20-day average volume of 35,355 shares. The stocks short-term moving averages (SMA 20: $1.12) suggest a recent uptick in price, while the medium-term (SMA 50: $1.46) and long-term (SMA 200: $1.88) averages indicate a downward trend over the past year. The Average True Range (ATR) of 0.14 reflects relatively low volatility in recent trading sessions.

Based on the provided data, here is a 3-month forecast:

Technical Data Outlook: The stocks SMA 20 crossing below SMA 50 and SMA 200 indicates a bearish trend. If the price fails to breach the SMA 50 level of $1.46, it may consolidate or decline further. The ATR of 0.14 suggests limited volatility, implying smaller price swings in the near term.

Fundamental Data Outlook: With a market cap of $49.21 million and a P/S ratio of 0.14, Mynd.ai is positioned as a micro-cap stock with potential for growth in the healthcare technology sector. The companys RoE of 9.41% suggests efficient operations, but the lack of forward P/E data indicates uncertainty about future earnings. Investors may await further financial disclosures to assess the companys growth trajectory.